Cargando…
Prostacyclin and thromboxane in benign and malignant breast tumours.
6-keto-PGF1 alpha and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001625/ https://www.ncbi.nlm.nih.gov/pubmed/3530307 |
_version_ | 1782135643050082304 |
---|---|
author | Laekeman, G. M. Vergote, I. B. Keersmaekers, G. M. Heiremans, J. Haensch, C. F. de Roy, G. Uyttenbroeck, F. L. Herman, A. G. |
author_facet | Laekeman, G. M. Vergote, I. B. Keersmaekers, G. M. Heiremans, J. Haensch, C. F. de Roy, G. Uyttenbroeck, F. L. Herman, A. G. |
author_sort | Laekeman, G. M. |
collection | PubMed |
description | 6-keto-PGF1 alpha and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic-disease tissues (P less than 0.05). The 6-keto-PGF1 alpha/TXB2 ratio was higher in carcinomata than in normal tissues and fibroadenomata (P less than 0.05) but was not significantly different from the ratio in sclerocystic disease. The prostaglandin levels and the 6-keto-PGF1 alpha/TXB2 ratios from carcinomata did not correlate significantly with age, tumour size, differentiation, lymph node status, nuclear-cytoplasmic ratio, host cell reaction, mast cells, necrosis, elastosis, fibrosis or blood vessel density. Lower nuclear density was associated with lower 6-keto-PGF1 alpha/TXB2 ratios (P = 0.01) whereas the latter value was higher when infiltration was lower (P = 0.03). There was a positive correlation between mitotic index and the 6-keto-PGF1 alpha/TXB2 ratio (P = 0.04). Cumulation of variables revealed lower prostanoid ratios in tumours greater than 2 cm without lymph node metastasis then tumours less than 2 cm with lymph node metastasis (P = 0.04). A first follow-up (14 months) showed a higher 6-keto-PGF1 alpha/TXB2 ratio in patients who developed metastasis (P = 0.04). Our study does not confirm the hypothesis that high prostacyclin levels are a good prognostic index in breast cancer. |
format | Text |
id | pubmed-2001625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1986 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20016252009-09-10 Prostacyclin and thromboxane in benign and malignant breast tumours. Laekeman, G. M. Vergote, I. B. Keersmaekers, G. M. Heiremans, J. Haensch, C. F. de Roy, G. Uyttenbroeck, F. L. Herman, A. G. Br J Cancer Research Article 6-keto-PGF1 alpha and thromboxane B2 were determined by radioimmunoassay in 37 extracts of breast carcinomata, 8 fibroadenomata, 12 sclerocystic-disease specimens and 51 normal breast tissues. More prostanoids were extracted from carcinomata than from normal specimens, fibroadenomata or sclerocystic-disease tissues (P less than 0.05). The 6-keto-PGF1 alpha/TXB2 ratio was higher in carcinomata than in normal tissues and fibroadenomata (P less than 0.05) but was not significantly different from the ratio in sclerocystic disease. The prostaglandin levels and the 6-keto-PGF1 alpha/TXB2 ratios from carcinomata did not correlate significantly with age, tumour size, differentiation, lymph node status, nuclear-cytoplasmic ratio, host cell reaction, mast cells, necrosis, elastosis, fibrosis or blood vessel density. Lower nuclear density was associated with lower 6-keto-PGF1 alpha/TXB2 ratios (P = 0.01) whereas the latter value was higher when infiltration was lower (P = 0.03). There was a positive correlation between mitotic index and the 6-keto-PGF1 alpha/TXB2 ratio (P = 0.04). Cumulation of variables revealed lower prostanoid ratios in tumours greater than 2 cm without lymph node metastasis then tumours less than 2 cm with lymph node metastasis (P = 0.04). A first follow-up (14 months) showed a higher 6-keto-PGF1 alpha/TXB2 ratio in patients who developed metastasis (P = 0.04). Our study does not confirm the hypothesis that high prostacyclin levels are a good prognostic index in breast cancer. Nature Publishing Group 1986-09 /pmc/articles/PMC2001625/ /pubmed/3530307 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Laekeman, G. M. Vergote, I. B. Keersmaekers, G. M. Heiremans, J. Haensch, C. F. de Roy, G. Uyttenbroeck, F. L. Herman, A. G. Prostacyclin and thromboxane in benign and malignant breast tumours. |
title | Prostacyclin and thromboxane in benign and malignant breast tumours. |
title_full | Prostacyclin and thromboxane in benign and malignant breast tumours. |
title_fullStr | Prostacyclin and thromboxane in benign and malignant breast tumours. |
title_full_unstemmed | Prostacyclin and thromboxane in benign and malignant breast tumours. |
title_short | Prostacyclin and thromboxane in benign and malignant breast tumours. |
title_sort | prostacyclin and thromboxane in benign and malignant breast tumours. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001625/ https://www.ncbi.nlm.nih.gov/pubmed/3530307 |
work_keys_str_mv | AT laekemangm prostacyclinandthromboxaneinbenignandmalignantbreasttumours AT vergoteib prostacyclinandthromboxaneinbenignandmalignantbreasttumours AT keersmaekersgm prostacyclinandthromboxaneinbenignandmalignantbreasttumours AT heiremansj prostacyclinandthromboxaneinbenignandmalignantbreasttumours AT haenschcf prostacyclinandthromboxaneinbenignandmalignantbreasttumours AT deroyg prostacyclinandthromboxaneinbenignandmalignantbreasttumours AT uyttenbroeckfl prostacyclinandthromboxaneinbenignandmalignantbreasttumours AT hermanag prostacyclinandthromboxaneinbenignandmalignantbreasttumours |